5 Papers
14 Citations
CE Geyer is an academic researcher from University of North Carolina at Chapel Hill. The author has contributed to research in topics: Internal medicine & Breast cancer. The author has an hindex of 1, co-authored 1 publications.
Chat about Author
Papers
Genomic characterisation of hormone receptor-positive breast cancer arising in very young women.
Stephen J Luen,Giuseppe Viale,Serena Nik-Zainal,Peter Savas,Roswitha Kammler,Patrizia Dell'Orto,O.M. Biasi,Andrea Degasperi,Lauren C. Brown,I Lang,Gaëtan MacGrogan,Carlo Tondini,Meritxell Bellet,Federica Villa,Antonio Bernardo,Eva Ciruelos,Per Karlsson,Patrick Neven,M. Climent,B. M. Müller,W. Joshum,Hervé Bonnefoi,Silvana Martino,Nancy E. Davidson,CE Geyer,S Chia,James N. Ingle,Roger Coleman,Christine Solbach,Beat Thürlimann,Marco Colleoni,Alan S. Coates,Aron Goldhirsch,Gini F. Fleming,PA Francis,Terence P. Speed,Mm Regan,Sherene Loi +37 more
TL;DR: Genomic alterations were characterised using next-generation sequencing from a subset of 1276 patients (deep targeted sequencing, n = 1258; whole-exome sequencing in a young-age, case-control subsample,n = 82) to determine genomic drivers that are enriched in young premenopausal women as discussed by the authors .
22
Abstract GS4-07: Race, ethnicity and clinical outcomes in hormone receptor-positive, HER2-negative, node-negative breast cancer: results from the TAILORx trial
Kathy S. Albain,Robert Gray,Joseph A. Sparano,DF Makower,KI Pritchard,DF Hayes,CE Geyer,EC Dees,MP Goetz,JA Olson,T. Lively,Sunil Badve,T.J. Saphner,LI Wagner,Timothy J. Whelan,MJ Ellis,S Paik,William C. Wood,Peter M. Ravdin,M. Keane,Henry L. Gomez,Pavan S. Reddy,Timothy F. Goggins,IA Mayer,AM Brufsky,DL Toppmeyer,VG Kaklamani,JL Berenberg,Jeffrey S. Abrams,GW Sledge +29 more
TL;DR: In patients eligible and selected for participation in TAILORx, black women had worse clinical outcomes despite similar 21-gene assay RS results and comparable systemic therapy, adding to an emerging body of evidence suggesting a biologic basis or other factors contributing to racial disparities in HR-positive breast cancer that requires further evaluation.
15
Reply to the Letter to the Editor "Risk of MDS/AML with the addition of neoadjuvant carboplatin to standard chemotherapy for triple negative breast cancer" by A. Okines and N. Turner.
TL;DR: Okines et al. as discussed by the authors found that the risk of acute myeloid leukemia/myelodysplastic syndrome (AML/MDS) and other second malignancies was not increased by adding carboplatin or veliparib to the anthracycline-based control regimen.
Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data from BrighTNess, a randomized phase 3 trial.
CE Geyer,William M. Sikov,Jens Huober,Hope S. Rugo,Norman Wolmark,Joyce O'Shaughnessy,David Maag,Michael Untch,Mehra Golshan,Jose Juan Ponce Lorenzo,Otto Metzger,Martin Dunbar,W. Fraser Symmans,PS Rastogi,J. Sohn,Robyn R. Young,Gail S. Wright,C. Harkness,Kristi McIntyre,Denise A. Yardley,Sibylle Loibl +20 more
TL;DR: The BrighTNess trial as discussed by the authors showed that the addition of carboplatin with/without veliparib to neoadjuvant chemotherapy significantly improved pathological complete response (pCR) rates with manageable acute toxicity in patients with triple-negative breast cancer (TNBC).
VP1-2022: Pre-specified event driven analysis of Overall Survival (OS) in the OlympiA phase III trial of adjuvant olaparib (OL) in germline BRCA1/2 mutation (gBRCAm) associated breast cancer
A. Tutt,James Garber,R. D. Gelber,Kelly-Anne Phillips,Andrea Eisen,Oskar T. Johannsson,PS Rastogi,Karen Y. Cui,Sa Im,Rinat Yerushalmi,Adam Brufsky,M Taboada,G. Rossi,Greg Yothers,Cf. Singer,Luis Fein,Niklas Loman,D. Cameron,Carolyn Campbell,CE Geyer +19 more
TL;DR: OlympiA as discussed by the authors is the first randomized clinical trial to test a PARP inhibitor as adjuvant therapy and showed that OL significantly improved the primary endpoint of invasive disease-free survival (IDFS) and secondary endpoint of distant DFS (DDFS) compared with placebo (PL).